Summary
The effect of the ergot derivative bromocriptine (5 mg orally) on blood pressure and plasma catecholamine concentrations was explored in normal volunteers. A significant decrease of plasma noradrenaline was found, while dopamine and adrenaline concentrations did not change significantly. Systolic and diastolic blood pressures were significantly lowered at 150 min after administration. The hypotensive effect of bromocriptine seems to be mediated by a lowered release of noradrenaline from sympathetic nerve endings. It may be hypothesized that the drug stimulates presynaptic dopamine receptors located on postganglionic sympathetic nerves, thus inhibiting noradrenaline discharge.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96
Greenacre JK, Teychenne PF, Petrie A, Calne DB, Leigh PN, Reid JL (1976) The cardiovascular effects of bromocriptine in Parkinsonism. Br J Clin Pharmacol 3: 571–574
Kaye SB, Shaw KM, Ross EJ (1976) Bromocriptine and hypertension. Lancet 2: 1176–1177
Stumpe KO, Kolloch R, Higuchi M, Kruch F, Vetter H (1977) Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Lancet 2: 211–214
Steardo L, Sorge F, Florio C, Marano E, Bonuso S, De Martino G (1978) Effetti sulla pressione arteriosa della somministrazione di una unica dose (5 mg/os) di bromoscriptina. Quad Acta Neurol 37: 98–104
Steardo L, Marano E, Sorge F (1979) Bromocriptine blood-pressure lowering effect in migraine patients. Acta Neurol 1: 379–386
Lokhandwala MF, Tadepalli AS, Jandhyala BS (1979) Cardiovascular actions of bromocriptine: evidence for a neurogenic mechanism. J Pharmacol Exp Ther 211: 620–625
Sved AF, Fernstrom JD (1980) Evidence for a peripheral dopaminergic mechanism in the antihypertensive effect of lergotrile. Life Sci 27: 349–354
Volkman PH, Goldberg LI (1978) Lack of correlation between inhibition of prolactine release and stimulation of dopaminergic renal vasodilatation. Gen Pharmacol 9: 223–227
Hamilton TC (1981) Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats. Br J Pharmacol 72: 419–425
Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O (1979) Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 25: 137–142
Van Loon GR, Sole MJ, Bain J, Ruse JL (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425–434
Da Prada M, Zurcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline an dopamine within the fentomole range. Life Sci 19: 1161–1174
Bybee DE, Wiesen M, Aronin N, Krieger DT, Frohman LA, and Kopin IJ (1982) Failure of bromocriptine to lower plasma catecholamines in normal men and women. J Clin Endocrinol Metab 54 [3]: 648–650
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steardo, L., Di Stasio, E., Bonuso, S. et al. The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers. Eur J Clin Pharmacol 29, 713–715 (1986). https://doi.org/10.1007/BF00615964
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615964